You are here

  • Home
  • Archive
  • Volume 10, Issue 2
  • Third-generation anti-CD19 chimeric antigen receptor T-cells incorporating a TLR2 domain for relapsed or refractory B-cell lymphoma: a phase I clinical trial protocol (ENABLE)

Citation Tools

Article menu

Download PDFPDF

XML
Haematology (incl blood transfusion)
Protocol
Third-generation anti-CD19 chimeric antigen receptor T-cells incorporating a TLR2 domain for relapsed or refractory B-cell lymphoma: a phase I clinical trial protocol (ENABLE)

Download to a citation manager

Download the citation for this article by clicking on one of the following citation managers:

Cite this article as:
George P, Dasyam N, Giunti G, et al
Third-generation anti-CD19 chimeric antigen receptor T-cells incorporating a TLR2 domain for relapsed or refractory B-cell lymphoma: a phase I clinical trial protocol (ENABLE)
BMJ Open 2020;10:e034629. doi: 10.1136/bmjopen-2019-034629